Biosciences to launch $40M Series A at JPM 2026, advancing CS-0003 mucosal-immune therapies for GI SSI and the GB platform.

Jinxing Li and Christopher H. Contag delve into magnetobiology, which utilizes magnetic fields to manipulate and control ...

Using ribosome engineering (RE), researchers from Shinshu University introduced mutations affecting the protein synthesis ...

Neurodegenerative diseases, traditionally viewed as driven by neuronal decline, are increasingly recognized to involve ...

Cell cycle checkpoint-related genes (CCCRGs) are implicated in the development and progression of hepatocellular carcinoma ...

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and begins in the cells lining the ...

Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...

Published in Volume 1 of the journal Immunity & Inflammation on December 18, 2025, the article "Reinventing brain immunity in neurodegeneration ...

WASHINGTON - We're deep into cold and flu season, and you're likely reaching for any immune-boosting foods you can find.

New research published in the peer-reviewed science journal, Immuno, reports that Hericium erinaceus (Lion's Mane) ...

Multiple sclerosis (MS) is a chronic neurological disease characterized by nerve damage and consequent impairments in vision, ...

Partnership Leverages Callan JMB's Federal Contract Experience, Cold Chain Infrastructure, and Strategic National Stockpile Relationships to ...